Indeed, in the presence of murlentamab-opsonized tumor cells, macrophages adopt a pro-inflammatory profile (secreting IL12, TNFα, IL6, IL1β, IFNγ, CXCL9 and CXCL10) with the overexpression of surface receptors characteristic of the M1 polarization (CD80, TLR2) while downregulating several M2-like markers (CD163, CD206, CD36 and IL10). Here, CXCL9 is linked to neoplasm.